Last reviewed · How we verify
Preserved drop treatment
At a glance
| Generic name | Preserved drop treatment |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension (PHASE2)
- Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease (EARLY_PHASE1)
- Clinical Trial for the Evaluation of Safety and Efficacy of Drop 0.4% (PHASE3)
- Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer (PHASE2)
- Artificial Tears, Tear Lipids and Tear Film Dynamics (PHASE4)
- Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. (PHASE2, PHASE3)
- Comparison of Treatment With Preservative-free Dexamethasone 0.1% (Monofree Dexamethason) and Diclofenac 0.1% (Dicloabak) Eye Drops Versus Preserved Dexamethasone 0.1% (Maxidex) and Diclofenac 0.1% (Voltaren Ophtha) Eye Drops After Cataract Surgery (PHASE4)
- The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Preserved drop treatment CI brief — competitive landscape report
- Preserved drop treatment updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI